NeuroTrax Science Team and Glen M. Doniger, PhD

In clinical and forensic neuropsychology, it’s not just about identifying a patient’s cognitive profile, but determining whether those results accurately reflect their true level of function.

This distinction becomes especially important in cases involving traumatic brain injury (TBI), disability evaluations, and litigation, where cognitive findings may directly influence legal and financial outcomes. In these contexts, performance validity, or the extent to which test results reflect genuine effort, is essential [1].

Neuropsychological assessments rely on active participation. When effort is reduced, inconsistent, or intentionally manipulated, results can misrepresent cognitive ability. In forensic settings, where external incentives may influence behavior, this creates a significant risk.

NeuroTrax addresses this challenge through an embedded, empirically derived algorithm designed to estimate probability of high negative response bias (H-NRB), indicative of non-credible performance. The underlying algorithm has been validated in a litigating TBI population and shown to correctly classify up to 94.7% of cases, with 98.0% specificity in distinguishing genuine impairment from malingering [2]. This level of accuracy provides clinicians and legal professionals with greater confidence when interpreting cognitive data in high-stakes scenarios.

Beyond overall probability, NeuroTrax facilitates detection of performance patterns inconsistent with known neurological conditions [2,3]. One study comparing individuals simulating cognitive impairment with genuinely impaired patients showed that simulators often produced atypical or “unlikely” profiles [3]. These may include failure to improve across repeated memory trials or abnormal interference patterns in executive function tasks such as the Stroop paradigm. These inconsistencies are difficult to reproduce consistently, even when individuals are coached.

NeuroTrax enhances detection by capturing both accuracy and millisecond-level response times across multiple cognitive domains. This level of granularity creates a detailed performance signature that is difficult to fabricate, reinforcing its value in forensic psychiatry and neuropsychology.

A key strength of NeuroTrax in forensic applications is its standardized and automated administration. Unlike traditional neuropsychological assessments, which may be influenced by examiner variability, NeuroTrax delivers a uniform testing experience with automated scoring. This reduces bias and supports the level of objectivity required for expert testimony and legal admissibility [1].

The platform is also supported by a normative database with adjustment for age and education, allowing clinicians to interpret results against well-defined benchmarks. This enables the ability to distinguish true cognitive impairment from non-credible performance. The forensic utility of NeuroTrax is grounded in its robust scientific validation [1]. The battery has demonstrated strong construct validity, reflected by convergence with established neuropsychological measures [4,5], supporting its clinical relevance. It also shows high test-retest reliability, which is critical in legal contexts where consistency over time may be scrutinized [6,7].

Additionally, the platform has been used extensively in research and clinical practice, with a growing body of peer-reviewed literature supporting its use across neurological and psychiatric populations.

Performance validity is central to ensuring that cognitive data is trustworthy. Without it, there is a risk of misclassification, particularly overestimating impairment in cases of malingering. In forensic and TBI settings, this can have significant consequences for diagnosis, treatment, and legal outcomes.

By integrating cognitive assessment with embedded validity measures, NeuroTrax provides a more complete picture of patient performance. It enables clinicians to assess not only how a patient performs, but whether that performance is credible.

References:

[1] Russell, E.W. (2012). The Scientific Foundation of Neuropsychological Assessment: With Applications to Forensic Evaluation. London: Elesvier. DOI: 10.1016/C2011-0-04279-5

[2] Bar-Hen, M., Doniger, G.M., Golzad, M., Geva, N., and Schweiger, A. (2015). Empirically derived algorithm for performance validity assessment embedded in a widely used neuropsychological battery: Validation among TBI patients in litigation. Journal of Clinical and Experimental Neuropsychology, 37(10), 1086–1097. DOI: 10.1080/13803395.2015.1078294

[3] Hegedish, O., Doniger, G.M., and Schweiger, A. (2012). Detecting response bias on the NeuroTrax battery. Psychiatry, Psychology and Law, 19(2), 262–282. DOI: 10.1080/13218719.2011.561767

[4] Doniger, G.M., Simon, E.S., Okun, M.S., Rodriguez, R.L., Jacobson, C.E., Weiss, D., Rosado, C., and Fernandez, H.H. (2006). Construct validity of a computerized neuropsychological assessment in patients with movement disorders. Movement Disorders, 21(S15), S656-S657. DOI: 10.1002/mds.21249

[5] Golan, D., Wilken, J., Doniger, G.M., Fratto, T., Kane, R., Srinivasan, J., Zarif, M., Bumstead, B., Buhse, M., Fafard, L., Topalli, I., and Gudesblatt, M. (2019). Validity of a multi-domain computerized cognitive assessment battery for patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 30, 154–162. DOI: 10.1016/j.msard.2019.01.051

[6] Schweiger, A., Doniger, G.M., Dwolatzky, T., Jaffe, D., and Simon, E.S. (2003). Reliability of a novel computerized neuropsychological battery for mild cognitive impairment. Acta Neuropsychologica, 1(4), 407–413. GICID: 01.3001.0001.0603

[7] Melton, J.L. (2005). NEDU Technical Report 06-10, Navy Experimental Diving Unit, Panama City, FL.

NeuroTrax Science Team and Glen M. Doniger, PhD

Sleep is often treated as a lifestyle issue, but the evidence tells a more serious story. Sleep quality, sleep duration, and daytime sleepiness all have measurable effects on cognitive performance, particularly attention, processing speed, memory, and executive function.

A newly published University of Miami study using NeuroTrax highlights this point. The MAGNETO study evaluated adults with obstructive sleep apnea (OSA) whose primary respiratory symptoms were effectively managed by adherence to positive airway pressure (PAP) therapy. Still, many participants showed objective residual excessive daytime sleepiness (EDS). Importantly, this sleepiness was associated with poorer performance in global cognition and multiple NeuroTrax cognitive domains, including memory, executive function, attention, and processing speed [1].

Patients with objective EDS performed 0.43 to 0.58 standard deviations worse on NeuroTrax measures compared to those without EDS. This difference is considered clinically meaningful and is roughly equivalent to a 1–2 point shift on brief screening tools like the MoCA or MMSE [1].

Good sleep is not just about feeling rested. It supports the cognitive functions people rely on every day: staying focused, processing information efficiently, retaining information, and making decisions.

The MAGNETO study is particularly relevant because it shows that cognitive risk can persist even when OSA treatment appears successful by respiratory measures. PAP adherence and normal apnea indices did not necessarily translate into restored cognitive performance [1]. This highlights an important gap in care: without objective cognitive assessment, residual impairment may go undetected.

NeuroTrax has been used to quantify how sleep disruption affects cognition in multiple studies.

In adolescents, Cohen-Zion et al. demonstrated that even modest sleep restriction (6 to 6.5 hours per night) resulted in significantly poorer performance in information processing speed, executive function, attention, and motor skills compared to extended sleep conditions (10 to 10.5 hours) [2]. Under optimal sleep conditions, participants were able to maintain performance even as task difficulty increased, a benefit that disappeared under sleep restriction [2].

In a neurological population, Sater et al. showed that sleep efficiency measured via polysomnography was significantly associated with NeuroTrax global cognitive scores, executive function, and information processing in patients with multiple sclerosis [3]. The study additionally found that fragmented sleep, measured as increased wake after sleep onset (WASO), was linked to poorer verbal function performance [3].

Sleep-related cognitive impairment is also evident in demanding professional environments. Flinn et al. reported measurable declines in global cognition, attention, and processing speed in junior doctors following extended work hours and sleep deprivation [4]. These findings demonstrate that even highly trained individuals are vulnerable to the cognitive effects of insufficient sleep [4].

The key clinically is not just to show that sleep affects cognition, but to measure how cognition changes when sleep changes.

NeuroTrax enables detailed tracking across multiple cognitive domains, elucidating whether sleep disruption is affecting attention, processing speed, memory, executive function, or global cognition. This is particularly valuable in longitudinal monitoring of response to PAP therapy, behavioral sleep interventions, or changes in work schedules.

The MAGNETO study suggests that residual EDS may represent a distinct cognitive risk phenotype in treated OSA [1]. Two patients may appear equally well managed from a respiratory perspective, yet differ significantly in cognitive performance. Objective cognitive testing helps reveal that difference.

Sleep health should be considered a core component of cognitive wellness. Consistent sleep duration, reduced fragmentation, and effective management of sleep disorders all play a role in maintaining cognitive function.

The growing body of NeuroTrax sleep research points to a consistent conclusion: sleep disruption leads to measurable cognitive changes. With digital neurometrics like NeuroTrax, these changes can be objectively quantified, tracked, and ultimately addressed for improved daily function and quality of life.

References:

[1] Junco, B., Ramos, A., Hernandez-Cardenache, R., Wallace, D. M., Dib, S., Pérez Negrón, A. P., Vanderkley, A., and McIntosh, R. (2026). Cognition and psychomotor vigilance in treated sleep apnea patients with and without daytime sleepiness: The MAGNETO study. Journal of Clinical Sleep Medicine, 22​(1):60. DOI: 10.1007/s44470-026-00077-9

[2] Cohen-Zion, M., Shabi, A., Levy, S., Glasner, L., and Wiener, A. (2016). Effects of partial sleep deprivation on information processing speed in adolescence. Journal of the International Neuropsychological Society, 22(4), 388–398. DOI: 10.1017/S1355617716000072

[3] Sater, R. A., Gudesblatt, M., Kresa-Reahl, K., Brandes, D. W., and Sater, P. A. (2015). The relationship between objective parameters of sleep and measures of fatigue, depression, and cognition in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical, 1(2055217315577828). DOI: 10.1177/2055217315577828

[4] Flinn, F. and Armstrong, C. (2011). Junior doctors’ extended work hours and the effects on their performance: the Irish case. International Journal for Quality in Health Care, 23(2), 210–217. DOI: 10.1093/intqhc/mzq088